Literature DB >> 30630957

Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort.

Cristina Moglia1,2, Andrea Calvo1,2, Maurizio Grassano1, Antonio Canosa1, Umberto Manera1, Fabrizio D'Ovidio1, Alessandro Bombaci1, Enrica Bersano3, Letizia Mazzini3, Gabriele Mora4, Adriano Chiò5,2,6.   

Abstract

OBJECTIVES: To assess the role of body mass index (BMI) and of the rate of weight loss as prognostic factors in amyotrophic lateral sclerosis (ALS) and to explore the clinical correlates of weight loss in the early phases of the disease.
METHODS: The study cohort included all ALS patients in Piemonte/Valle d'Aosta in the 2007-2011 period. Overall survival and the probability of death/tracheostomy at 18 months (logistic regression model) were calculated.
RESULTS: Of the 712 patients, 620 (87.1%) were included in the study. Patients ' survival was related to the mean monthly percentage of weight loss at diagnosis (p<0.0001), but not to pre-morbid BMI or BMI at diagnosis. Spinal onset patients with dysphagia at diagnosis had a median survival similar to bulbar onset patients. About 20% of spinal onset patients without dysphagia at diagnosis had severe weight loss and initial respiratory impairment, and had a median survival time similar to bulbar onset patients.
CONCLUSIONS: The rate of weight loss from onset to diagnosis was found to be a strong and independent prognostic factor in ALS. Weight loss was mainly due to the reduction of nutritional intake related to dysphagia, but a subgroup of spinal onset patients without dysphagia at diagnosis had a severe weight loss and an outcome similar to bulbar patients. According to our findings, we recommend that in clinical trials patients should be stratified according to the presence of dysphagia at the time of enrolment and not by site of onset of symptoms. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  amyotrophic lateral sclerosis; body mass index; dysphagia; respiratory function; weight loss

Mesh:

Year:  2019        PMID: 30630957     DOI: 10.1136/jnnp-2018-319611

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

1.  Manifold learning for amyotrophic lateral sclerosis functional loss assessment : Development and validation of a prognosis model.

Authors:  Vincent Grollemund; Gaétan Le Chat; Marie-Sonia Secchi-Buhour; François Delbot; Jean-François Pradat-Peyre; Peter Bede; Pierre-François Pradat
Journal:  J Neurol       Date:  2020-09-04       Impact factor: 4.849

Review 2.  Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis.

Authors:  Andrew T Nelson; Davide Trotti
Journal:  Neurotherapeutics       Date:  2022-06-30       Impact factor: 6.088

Review 3.  Lipid Metabolic Alterations in the ALS-FTD Spectrum of Disorders.

Authors:  Juan Miguel Godoy-Corchuelo; Luis C Fernández-Beltrán; Zeinab Ali; María J Gil-Moreno; Juan I López-Carbonero; Antonio Guerrero-Sola; Angélica Larrad-Sainz; Jorge Matias-Guiu; Jordi A Matias-Guiu; Thomas J Cunningham; Silvia Corrochano
Journal:  Biomedicines       Date:  2022-05-10

4.  Alterations in metabolic biomarkers and their potential role in amyotrophic lateral sclerosis.

Authors:  Jin-Yue Li; Li-Ying Cui; Xiao-Han Sun; Dong-Chao Shen; Xun-Zhe Yang; Qing Liu; Ming-Sheng Liu
Journal:  Ann Clin Transl Neurol       Date:  2022-05-18       Impact factor: 5.430

5.  The feeding behaviour of Amyotrophic Lateral Sclerosis mouse models is modulated by the Ca2+ -activated KCa 3.1 channels.

Authors:  Germana Cocozza; Stefano Garofalo; Marta Morotti; Giuseppina Chece; Alfonso Grimaldi; Mario Lecce; Ferdinando Scavizzi; Rossella Menghini; Viviana Casagrande; Massimo Federici; Marcello Raspa; Heike Wulff; Cristina Limatola
Journal:  Br J Pharmacol       Date:  2021-10-05       Impact factor: 9.473

6.  Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target.

Authors:  Silvia Scaricamazza; Illari Salvatori; Giacomo Giacovazzo; Jean Philippe Loeffler; Frederique Renè; Marco Rosina; Cyril Quessada; Daisy Proietti; Constantin Heil; Simona Rossi; Stefania Battistini; Fabio Giannini; Nila Volpi; Frederik J Steyn; Shyuan T Ngo; Elisabetta Ferraro; Luca Madaro; Roberto Coccurello; Cristiana Valle; Alberto Ferri
Journal:  iScience       Date:  2020-04-21

Review 7.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

8.  Fat mass loss correlates with faster disease progression in amyotrophic lateral sclerosis patients: Exploring the utility of dual-energy x-ray absorptiometry in a prospective study.

Authors:  Ikjae Lee; Mohamed Kazamel; Tarrant McPherson; Jeremy McAdam; Marcas Bamman; Amy Amara; Daniel L Smith; Peter H King
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

9.  Body composition in amyotrophic lateral sclerosis subjects and its effect on disease progression and survival.

Authors:  Rup Tandan; Evan A Levy; Diantha B Howard; John Hiser; Nathan Kokinda; Swatee Dey; Edward J Kasarskis
Journal:  Am J Clin Nutr       Date:  2022-05-01       Impact factor: 8.472

Review 10.  Epidemiology of amyotrophic lateral sclerosis: an update of recent literature.

Authors:  Elisa Longinetti; Fang Fang
Journal:  Curr Opin Neurol       Date:  2019-10       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.